26.08.2010
- Sanofi-Aventis is not willing to pay more than $70 per share for U.S. biotech Genzyme and may look at alternative targets, Bloomberg reported on Wednesday, citing sources familiar...
24.08.2010
- U.S. biotechnology firm Genzyme and its French suitor Sanofi-Aventis are at odds over the threshold price at which Sanofi could begin the due diligence on Genzyme's books, the Wall...
23.08.2010
- The lack of new information about Sanofi Aventis' reported interest in acquiring Genzyme could mean the two sides have begun talks, according to Sanford Bernstein analyst Geoffrey...
18.08.2010
- Europe's pharmaceuticals industry, not known for industrial disputes, is experiencing a spate of clashes as employees fight back against cuts in jobs and benefits. Britain's second...
17.08.2010
- Biotechnology company Genzyme may be holding out for more money from suitor Sanofi-Aventis,but will find it difficult to persuade investors it is better off on its own. France's...
10.08.2010
- Swiss drugmaker Novartis received approval from EU regulators on Monday to buy a minority stake in Alcon, making it easier for it to take full control of the U.S. eyecare group...
09.08.2010
- Paris-based drugmaker Sanofi-Aventis may need weeks of haggling to get a deal on buying U.S. biotech firm Genzyme as the two appear wide apart over price. Neither party has...
04.08.2010
- Sanofi-Aventis has grabbed the headlines with its $18.4 billion bid for Genzyme, but the French drugmaker may be wiser to stick with smaller, bolt-on acquisitions. Sanofi is trying...
04.08.2010
- Sanofi-Aventis investors have urged the drugmaker not to pay more than about $19 billion to land Genzyme, some $10 a share below the price wanted by the U.S. biotech group. Two...
03.08.2010
- Sanofi-Aventis chief executive Chris Viehbacher should aim to land U.S. biotech group Genzyme for around$19 billion to keep his investors on side, according to institutional...
